0001589150
false
0001589150
2024-04-26
2024-04-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April
26, 2024
REGEN BIOPHARMA, INC.
(Exact name of small business
issuer as specified in its charter)
Nevada |
45-5192997 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Commission File No.
333-191725
4700 Spring Street, St
304, La Mesa, California 91942
(Address of Principal Executive
Offices)
(619) 722 5505
(Issuer’s telephone
number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
None |
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
On April 26th 2024 Regen Biopharma, Inc. ( the “Company”)
entered into an agreement with Value Quest, Inc. ( “Value Quest Agreement”). Pursuant to the Value Quest Agreement Value
Quest Inc. shall provide social media consulting services to the Company for a period of one year commencing on April 26, 2024.
Consideration to be paid to Value Quest, Inc. pursuant to the Value Quest Agreement shall be 20,068 shares of the Series A Preferred
stock of the Company.
The foregoing description of
the abovementioned Value Quest Agreement is not complete and is qualified in its entirety by reference to the text of the abovementioned
agreement which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
Item 8.01 Other Events.
On April 26, 2024 the Company and BST Partners ( Sublessor) agreed
to amend that sublease agreement (“Sublease Agreement”) entered into between the parties as follows:
The Company agreed that in addition to the base rent of $5,000 per
month to be paid by the Company to Sublessor the Company shall also reimburse Sublessor for any and all shared expenses as such term is
defined within the Sublease Agreement.
On January 13, 2022 the Company entered into the Sublease Agreement
whereby the Company would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from the Sublessor on
a month to month basis for $5,000 per month beginning January 14, 2022.
BST Partners is controlled by David Koos who serves as the sole officer
and director of Regen Biopharma, Inc.
The foregoing description of the abovementioned amendment and Sublease
Agreement are not complete and are qualified in their entirety by reference to the text of the abovementioned amendment and Sublease Agreement
which are attached to this Current Report on Form 8-K as Exhibit 10.2 and 10.3 and incorporated in this Item 8.01 by reference.
Item 3.02 Unregistered Sales of Equity Securities
On April 26th 2024 Regen Biopharma, Inc. ( the “Company”)
entered into an agreement with Value Quest, Inc. ( “Value Quest Agreement”). Pursuant to the Value Quest Agreement Value Quest
Inc. shall provide social media consulting services to the Company for a period of one year commencing on April 26, 2024.
Consideration to be paid to Value Quest, Inc. pursuant to the Value Quest Agreement shall be 20,068 shares of the Series A Preferred stock
of the Company.
The foregoing description of
the abovementioned Value Quest Agreement is not complete and is qualified in its entirety by reference to the text of the abovementioned
agreement which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 3.02 by reference.
Item 9.01 Financial
Statements and Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
REGEN BIOPHARMA, INC. |
|
|
Dated: April 29, 2024
|
By: /s/ David Koos |
EXHIBIT 10.1
Consultant’s Fee Agreement
AGREEMENT (“Agreement”) made this 26th day of April, 2024
by and between Value Quest, Inc. ( a Maryland corporation) hereinafter referred to as the "Consultant", and Regen BioPharma,
Inc.(a Nevada corporation), hereinafter referred to as the "Company”. Company and Consultant may be collectively referred to
as “Parties” and individually referred to as “Party”.
WHEREAS the Company desires to engage the Consultant perform certain
tasks relating to the development, marketing and promotion of the Company’s business through social media (“Social Media Consulting”).
WHEREAS, Consultant, upon mutual execution of this Agreement will provide
Social Media Consulting services to the Company
NOW, THEREFORE, it is agreed as follows:
1. Term.
The respective duties and obligations of the contracting parties shall
be for a period of one year commencing on April 26, 2024.
2. Duties of Consultant.
Consultant shall assist the Company in customizing and managing the following:
Facebook Page for the Company
Twitter Account for the Company
3. Compensation.
The Consultant shall receive a Consultant’s Fee consisting of
________ shares of the Series A Preferred stock of the Company (“Consultant’s Fee”)
Company shall not be liable to the Consultant for any payment or reimbursement
other than the Consultant’s Fee.
4. Representations And Warranties Of Company.
a) Company is a corporation duly organized, validly existing and in
good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or
governmental agency which consent has not been obtained.
(b) The execution, delivery and performance of this Agreement by Company
does not and shall not constitute Company’s breach of any statute or regulation or ordinance of any governmental authority, and
shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction,
decree, contract, agreement, or instrument to which the Company is a party, or by which Company is or may be bound.
5. Representations And Warranties Of Consultant.
a) Consultant is a corporation duly organized, validly existing and
in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or
governmental agency which consent has not been obtained.
(b) The execution, delivery and performance of this Agreement by Consultant
does not and shall not constitute Consultant’s breach of any statute or regulation or ordinance of any governmental authority, and
shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction,
decree, contract, agreement, or instrument to which the Consultant is a party, or by which Consultant is or may be bound.
6. Restricted Securities Acknowledgment
Consultant acknowledges that any securities issued pursuant to this
Agreement that shall not be registered pursuant to the Securities Act of 1933 shall constitute “restricted securities” as
that term is defined in Rule 144 promulgated under the Securities Act of 1933, and shall contain the following restrictive legend:
“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED
OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”
7. Entire Agreement
This Agreement constitutes a final written expression of all the terms
of the Agreement between the parties regarding the subject matter hereof, are a complete and exclusive statement of those terms, and supersedes
all prior and contemporaneous Agreements, understandings, and representations between the parties.
8. Governing Law, Venue, Waiver Of Jury Trial
All questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of
California, without regard to the principles of conflicts of law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in California for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is
improper or inconvenient venue for such proceeding. If either party shall commence an action or proceeding to enforce any provisions of
this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys’
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS WHEREOF, the parties have hereunto executed this
Agreement on the 26th day of April, 2024.
By: |
|
|
|
|
|
Company |
|
|
|
|
|
/s/ David Koos |
|
|
David Koos, CEO |
|
|
Regen BioPharma, Inc. |
|
|
|
|
|
|
|
|
Consultant |
|
|
|
|
|
/s/ James Hibbert |
|
|
Value Quest Inc. |
|
|
EXHIBIT 10.2
AMENDMENT ( “Amendment”) TO SUBLEASE AGREEMENT BY AND BETWEEN
REGEN BIOPHARMA, INC. AND BST PARTNERS
WHEREAS
1) Regen BioPharma, Inc. (“Subtenant”) and BST Partners (Sublessor) are party to that sublease agreement (“Sublease
Agreement”) effective as of January 14, 2022
2) Subtenant agrees that in addition to the base rent of $5,000 per
month to be paid by Subtenant to Sublessor Subtenant shall also reimburse Sublessor for any and all shared expenses as such termmis defined
within the original lease agreement by and between the Sublessor and CIF LaMesa LLP beginning January 1, 2024.
3) Sublessor and Subtenant agree that except as otherwise specifically
modified in this Amendment, the Sublease Agreement has not been modified, supplemented, amended, or otherwise changed in any way and the
Sublease Agreement remains in full force and effect between the parties hereto as modified by this Amendment. To the extent of any inconsistency
between the terms and conditions of the Sublease Agreement and the terms and conditions of this Amendment, the terms and conditions of
this Amendment shall apply and govern the parties,
AGREED TO BY:
BST PARTNERS, Inc. |
REGEN BIOPHARMA,INC. |
|
|
By:/s/ David Koos |
By:/s/ David Koos |
Chairman and CEO |
Chairman and CEO |
|
|
4/26/2024 |
4/26/2024 |
Exhibit 10.3
SUBLEASE AGREEMENT
This is an agreement to sublet office space located
at 4 700 Spring Street, Suite 304, La Mesa, California 9 I 942 according to the terms specified below.
The sublessor agrees to sublet and the subtenant
agrees to take the premises described below. Both parties agree to keep, perform and fulfill the promises, conditions and agreements below:
1. The sublessor is: BST Partners
2. The subtenant is: Regen BioPharma, Inc.
3. The term of this sublease is month to month
beginning January 14, 2022.
4. The rent payable to the sublessor by the subtenant
is equal to FiveThousand Dollars per month ($5,000) is to be paid in at such time specified in accordance with the original lease agreement
between the sublessor and the lessor.
5. All charges for utilities connected with premises
which are to be paid by the sublessor under the master lease shall be paid by the subtenant for the term of this sublease to the extent
that such charges exceed the difference between the rent payable to the lessor by the sublessor under the master lease and the rent payable
to the sublessor by the subtenant shall be paid by the subtenant for the term of this sublease.
6. Subtenant agrees to surrender and deliver to
the sublessor the premises and all furniture and decorations within the premises in as good a condition as they were at the beginning
of the term, reasonable wear and tear excepted. The subtenant will be liable to the sub lessor for any damages occurring to the premises
or the contents thereof or to the building which are done by the subtenant.
7. In the event of any legal action concerning
this sublease, the losing party shall pay to the prevailing party reasonable attorney's fees and court costs to be fixed by the court
wherein such judgment shall be entered. The parties hereby bind themselves to this agreement by their signatures affixed below on this
13th day of January, 2022.
AGREED TO BY:
BST PARTNERS, Inc. |
REGEN BIOPHARMA,INC. |
|
|
By:/s/ David Koos |
By:/s/ David Koos |
Chairman and CEO |
Chairman and CEO |
v3.24.1.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Regen Biopharma (PK) (USOTC:RGBPD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Regen Biopharma (PK) (USOTC:RGBPD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024